Siegfried Hofmann reports on the pharmaceuticals and chemicals branches from Frankfurt.
Bayer has had a horrible six months, with its stock price dropping nearly 40 percent. Now its CEO wants to recapture the narrative and persuade investors that the company is a great long-term bet.
German biotech firm Morphosys has reported promising findings from a clinical trial of its Mor208 antibody to treat B-cell lymphoma, boosting the prospects of the drug getting approved — and opening up a potential €800 million market in the US alone.
In a bid to reboot its sluggish performance, the pharmaceutical and agribusiness giant has announced cuts of 10 percent of its global workforce and the disposal of underperforming divisions.
The good times are over in the country's heavyweight chemical sector, due to a dangerous cocktail of weakening demand in key markets and rising raw materials prices.
The drug maker’s plunge on the US market keeps causing headaches, triggering a 10-percent stock slump. A US judge did not annul a verdict that the weedkiller Roundup, inherited in the Monsanto takeover, causes cancer.
Alarmed investors wipe €10 billion off Bayer’s market value after a US jury awarded $289 million to a plaintiff who claimed Monsanto’s glyphosate product caused his cancer.
A ruling by the EU's top court on a genetic engineering technique has left German scientists and agricultural businesses worried that they will fall behind US and Chinese rivals.
The value of the pharmaceutical industry in Germany is doubling. But drug companies need to move into the digital era in a hurry, if they want to keep profit margins high, a new study warns.
Martin Brudermüller, the new chief of the German chemicals giant, is betting that novel products rather than old faithfuls will be the key to the firm's success.
It's not the best known drug company in the world, but Germany's second-largest pharmaceutical producer has grand plans to boost sales by 40 percent in the next seven years.